Mycosis fungoides terminating in acute myelocytic leukemia

• Published in: Rinshō ketsueki Vol. 41; no. 9; p. 755
• Main Authors: Takeoka, Y, Yamane, T, Koh, K R, Ohta, K, Nakamae, H, Aoyama, Y, Hirose, A, Fujino, Y, Inoue, T, Hino, M, Tatsumi, N
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.09.2000
• Subjects: Female; Humans; Leukemia, Myeloid, Acute - etiology; Leukemia, Myeloid, Acute - pathology; Middle Aged; Mycosis Fungoides - drug therapy; Mycosis Fungoides - pathology; Neoplasms, Second Primary - etiology; Neoplasms, Second Primary - pathology; PUVA Therapy; Skin Neoplasms - drug therapy; Skin Neoplasms - pathology
• ISSN: 0485-1439
• DOI: 10.11406/rinketsu.41.755

A 57-year-old woman was admitted to our hospital with suspected leukemia in September 1999. In 1990, systemic erythema had occurred, and mycosis fungoides (MF) had been diagnosed by skin biopsy. Interferon-gamma therapy had not been effective, and the erythema had disappeared after treatment with psoralen and ultraviolet A (PUVA) therapy (1.46 J/cm2). The patient had subsequently done well with a course of topical steroids. On admission this time, the WBC count was 1,600/microliter with 6% blasts. The total nucleated cell count in a bone marrow aspirate was 43.1 x 10(4)/microliter, of which 86.2% were peroxidase-positive blasts. Acute myelocytic leukemia (AML) was diagnosed. Chromosomal analysis demonstrated abnormalities of 48, XX, +4, +8, +add(10)(p11), add(11)(q23) in 10 of 20 cells, and 51, idem, +6, +8, +21, +mar in 8 cells with mixed-lineage leukemia gene rearrangement. Therapies (radiation, chemotherapy and PUVA) for MF, and the altered immune response seen in patients with this disease, especially in the more advanced stages, collectively termed cutaneous T-cell lymphoma (CTCL), suggest that such patients may be at increased risk of a second primary malignancy. To our knowledge, AML has been reported in 8 MF patients including the present one. Attention should be given to the possibility of MF terminating in AML.